Kenvue Inc. (NYSE:KVUE) Given Average Rating of "Hold" by Analysts

Shares of Kenvue Inc. (NYSE:KVUE - Get Free Report) have been assigned a consensus recommendation of "Hold" from the thirteen analysts that are presently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $24.42.

A number of equities analysts have weighed in on KVUE shares. Royal Bank of Canada reiterated a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Redburn Atlantic assumed coverage on Kenvue in a report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price target for the company. Canaccord Genuity Group raised their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. UBS Group decreased their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Friday, February 7th. Finally, Barclays lowered their price target on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a report on Monday, April 14th.

Kenvue Stock Performance

Shares of NYSE:KVUE traded up $0.02 during trading on Tuesday, hitting $23.98. The stock had a trading volume of 14,097,083 shares, compared to its average volume of 17,037,896. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue has a 12-month low of $17.67 and a 12-month high of $24.46. The stock has a market capitalization of $46.01 billion, a price-to-earnings ratio of 45.25, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. The stock has a 50-day simple moving average of $23.09 and a two-hundred day simple moving average of $22.52.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities research analysts expect that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.42%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue's dividend payout ratio is presently 154.72%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in KVUE. Norges Bank acquired a new stake in shares of Kenvue in the fourth quarter valued at about $521,348,000. Starboard Value LP acquired a new stake in Kenvue in the 4th quarter valued at about $467,864,000. Franklin Resources Inc. lifted its stake in Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after purchasing an additional 16,269,721 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after purchasing an additional 10,682,003 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Kenvue by 3.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock worth $5,249,665,000 after purchasing an additional 8,211,748 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.